Nombre de documents

23

Curiculum Vitae


Article dans une revue23 documents

  • David Ternant, Nicolas Azzopardi, William Raoul, Theodora Bejan-Angoulvant, Gilles Paintaud. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clinical Pharmacokinetics, Springer Verlag, In press, 〈10.1007/s40262-018-0680-3〉. 〈hal-01821717〉
  • Mira Tout, Anne-Laure Gagez, Stéphane Lepretre, Valérie Gouilleux-Gruart, Nicolas Azzopardi, et al.. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics, Springer Verlag, 2017, 56 (6), pp.635 - 647. 〈10.1007/s40262-016-0470-8〉. 〈hal-01769807〉
  • Yoann Pointreau, Nicolas Azzopardi, David Ternant, Gilles Calais, Gilles Paintaud. Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2017, pp.567-72. 〈10.1097/FTD.0000000000000321〉. 〈hal-01769813〉
  • Christophe Arnoult, Guillaume Brachet, Diana Cadena Castaneda, Nicolas Azzopardi, Christophe Passot, et al.. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice. Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2017, 199 (2), pp.418 - 424. 〈10.4049/jimmunol.1601246〉. 〈hal-01769804〉
  • Morgane Caulet, Thierry Lecomte, Olivier Bouché, Jérôme Rollin, Valérie Gouilleux-Gruart, et al.. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics, Springer Verlag, 2016, 55 (11), pp.1381 - 1394. 〈10.1007/s40262-016-0406-3〉. 〈hal-01769811〉
  • David Ternant, Konstantinos Karmiris, Séverine Vermeire, Celine Desvignes, Nicolas Azzopardi, et al.. Pharmacokinetics of adalimumab in Crohn’s disease. European Journal of Clinical Pharmacology, Springer Verlag, 2015, 71 (9), pp.1155 - 1157. 〈10.1007/s00228-015-1892-1〉. 〈hal-01769822〉
  • Jérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, Michelle Boisdron-Celle, Nicolas Azzopardi, et al.. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics, Future Medicine, 2015, 16 (18), pp.2035 - 2043. 〈10.2217/pgs.15.139〉. 〈hal-01769816〉
  • Nicolas Azzopardi, Sophie Dupuis-Girod, David Ternant, Anne-Emmanuelle Fargeton, Isabelle Ginon, et al.. Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. mAbs, Taylor & Francis, 2015, 7 (3), pp.630 - 637. 〈10.1080/19420862.2015.1022693〉. 〈hal-01769884〉
  • G Guilleminault, N. Azzopardi, N Arnoult, N Sobilo, N Hervé, et al.. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. Journal of Controlled Release, Elsevier, 2014, 196, pp.344 - 354. 〈10.1016/j.jconrel.2014.10.003〉. 〈hal-01769891〉
  • Virginie Herve, Nathalie Rabbe, Laurent Guilleminault, Flora Paul, Laurène Schlick, et al.. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. mAbs, Taylor & Francis, 2014, 6 (6), pp.1638 - 1648. 〈10.4161/mabs.34454〉. 〈hal-01769888〉
  • Christophe Passot, Nicolas Azzopardi, Sylvaine Renault, Nadine Baroukh, Christophe Arnoult, et al.. Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. mAbs, Taylor & Francis, 2014, 5 (4), pp.614 - 619. 〈10.4161/mabs.24815〉. 〈hal-01769897〉
  • Nicolas Azzopardi, Maud François, Emeline Laurent, Gilles Paintaud, Beatrice Birmelé. Influence of plasma exchange on rituximab pharmacokinetics. British Journal of Clinical Pharmacology, Wiley, 2013, 76 (3), pp.486 - 488. 〈10.1111/bcp.12167〉. 〈hal-01769901〉
  • Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, et al.. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.. Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (19), pp.6329-37. 〈10.1158/1078-0432.CCR-11-1081〉. 〈hal-00720512〉
  • Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, et al.. Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients. Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (19), pp.6329 - 6337. 〈10.1158/1078-0432.CCR-11-1081〉. 〈hal-01769933〉
  • Agnes Maillet, Laurent Guilleminault, Etienne Lemarié, Stephanie Lerondel, Nicolas Azzopardi, et al.. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2011, 28 (9), pp.2147 - 2156. 〈10.1007/s11095-011-0442-5〉. 〈hal-01769936〉
  • Nicolas Azzopardi, Therry Lecomte, David Ternant, Michele Boisdron-Celle, Friedrich Piller, et al.. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Fundam. Clin. Pharmacol., 2011, 25, pp.34-34. 〈hal-00616314〉
  • D. Chu Miow Lin, D. Mulleman, N. Azzopardi, I. Griffoul-Espitalier, J.-P. Valat, et al.. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scand. J. Rheumatol., 2010, 39 (1), pp.97-98. 〈hal-00616813〉
  • D Chu Miow Lin, D. Mulleman, N. Azzopardi, G Griffoul-Espitalier, P Valat, et al.. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scandinavian Journal of Rheumatology, Taylor & Francis, 2010, 39 (1), pp.97 - 98. 〈10.3109/03009740903177745〉. 〈hal-01769938〉
  • Nicolas Ceze, David Ternant, Friedrich Piller, Danielle Degenne, Nicolas Azzopardi, et al.. An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. Ther. Drug Monit., 2009, 31 (5), pp.597-601. 〈hal-00616405〉
  • Agnes Maillet, Laurent Guilleminault, Nicolas Azzopardi, Jerome Montharu, Laurent Vecellio, et al.. Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab. J. Thorac. Oncol., 2009, 4 (9), pp.S600-S600. 〈hal-00616858〉
  • Nicolas Ceze, David Ternant, Friedrich Piller, Danielle Degenne, Nicolas Azzopardi, et al.. An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2009, 31 (5), pp.597 - 601. 〈10.1097/FTD.0b013e3181b33da3〉. 〈hal-01769948〉
  • Nicolas Ceze, David Ternant, Friedrich Piller, Danielle Degenne, Nicolas Azzopardi, et al.. An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2009, 31 (5), pp.597-601. 〈hal-00521871〉
  • Juliette Thariat, Nicolas Azzopardi, Frederic Peyrade, Vincent Launay-Vacher, Jose Santini, et al.. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J. Clin. Oncol., 2008, 26 (25), pp.4223-4225. 〈hal-00616934〉